Infliximab in the treatment of Crohn’s disease

Gilberto Poggiolia General Surgery Department; Policlinico S. Orsola; University of BolognaItalyCorrespondence[email protected]

Silvio Lauretia General Surgery Department; Policlinico S. Orsola; University of BolognaItaly

Massimo Campieria General Surgery Department; Policlinico S. Orsola; University of BolognaItaly;* Internal Medicine Department; Policlinico S. Orsola; University of BolognaItaly

Filippo Pierangelia General Surgery Department; Policlinico S. Orsola; University of BolognaItaly

Paolo Gionchettia General Surgery Department; Policlinico S. Orsola; University of BolognaItaly;* Internal Medicine Department; Policlinico S. Orsola; University of BolognaItaly

Federica Ugolinia General Surgery Department; Policlinico S. Orsola; University of BolognaItaly

Lorenzo Gentilinia General Surgery Department; Policlinico S. Orsola; University of BolognaItaly

Piero Bazzia General Surgery Department; Policlinico S. Orsola; University of BolognaItaly

Fernando Rizzelloa General Surgery Department; Policlinico S. Orsola; University of BolognaItaly;* Internal Medicine Department; Policlinico S. Orsola; University of BolognaItaly

Maurizio Cosciaa General Surgery Department; Policlinico S. Orsola; University of BolognaItaly

show all

Infliximab in the treatment of Crohn’s disease

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Infliximab in the treatment of Crohn’s disease

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date